

Rolando Herrero Acosta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214320/publications.pdf>

Version: 2024-02-01

311
papers

35,494
citations

2675

95
h-index

3732

179
g-index

315
all docs

315
docs citations

315
times ranked

22785
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium. <i>Oral Diseases</i> , 2023, 29, 1565-1578.	3.0	9
2	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. <i>Vaccine</i> , 2022, 40, 76-88.	3.8	15
3	Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for Helicobacter pylori Detection?. <i>Diagnostics</i> , 2022, 12, 133.	2.6	7
4	molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. <i>Nature Communications</i> , 2022, 13, 233.	12.8	20
5	Lifestyle and dietary factors associated with serologically detected gastric atrophy in a Caucasian population in the GISTAR study. <i>European Journal of Cancer Prevention</i> , 2022, 31, 442-450.	1.3	2
6	HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. <i>Npj Vaccines</i> , 2022, 7, 40.	6.0	1
7	Factors Associated with False Negative Results in Serum Pepsinogen Testing for Precancerous Gastric Lesions in a European Population in the GISTAR Study. <i>Diagnostics</i> , 2022, 12, 1166.	2.6	0
8	Different human papillomavirus types share early natural history transitions in immunocompetent women. <i>International Journal of Cancer</i> , 2022, 151, 920-929.	5.1	5
9	Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer. <i>Oral Diseases</i> , 2021, 27, 73-93.	3.0	31
10	Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review. <i>Preventive Medicine</i> , 2021, 143, 106323.	3.4	13
11	Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. <i>International Journal of Cancer</i> , 2021, 148, 1383-1393.	5.1	21
12	Comparison of immediate colposcopy, repeat conventional cytology and high-risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The ASCUSâ€¦COL trial. <i>International Journal of Cancer</i> , 2021, 148, 1394-1407.	5.1	5
13	Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 1576-1581.	4.0	7
14	Prevalence and Potential Risk Factors of Helicobacter pylori Infection among Asymptomatic Individuals in Kazakhstan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 597-602.	1.2	6
15	Recent progress in gastric cancer prevention. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101733.	2.4	21
16	Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes. <i>Vaccine</i> , 2021, 39, 4419-4422.	3.8	3
17	Reproducibility, Temporal Variability, and Concordance of Serum and Fecal Bile Acids and Short Chain Fatty Acids in a Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1875-1883.	2.5	8
18	Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer. <i>Cancer Epidemiology</i> , 2021, 75, 102020.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2021, 224, 503-516.	4.0	4
20	Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. <i>Nature Communications</i> , 2021, 12, 5945.	12.8	10
21	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 818-828.	6.3	19
22	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2020, 21, 1643-1652.	10.7	54
23	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. <i>Vaccine</i> , 2020, 38, 5997-6006.	3.8	11
24	How do international gastric cancer prevention guidelines influence clinical practice globally?. <i>European Journal of Cancer Prevention</i> , 2020, 29, 400-407.	1.3	4
25	Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. <i>British Journal of Cancer</i> , 2020, 123, 1456-1463.	6.4	65
26	Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2261-2268.	2.5	3
27	Regional variations in Helicobacter pylori infection, gastric atrophy and gastric cancer risk: The ENIGMA study in Chile. <i>PLoS ONE</i> , 2020, 15, e0237515.	2.5	12
28	Cervicovaginal microbiome and natural history of HPV in a longitudinal study. <i>PLoS Pathogens</i> , 2020, 16, e1008376.	4.7	150
29	Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1038-1046.	6.3	89
30	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1030-1037.	6.3	42
31	Psycho-social impact of positive human papillomavirus testing in Jujuy, Argentina results from the Psycho-Estampa study. <i>Preventive Medicine Reports</i> , 2020, 18, 101070.	1.8	13
32	Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. <i>BMJ Open</i> , 2020, 10, e035796.	1.9	17
33	Does Family History of Cancer Influence Undergoing Screening and Gastrointestinal Investigations?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 523-528.	0.9	1
34	Title is missing!. , 2020, 15, e0237515.		0
35	Title is missing!. , 2020, 15, e0237515.		0
36	Title is missing!. , 2020, 15, e0237515.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0237515.		0
38	Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. <i>Journal of Infectious Diseases</i> , 2019, 219, 41-49.	4.0	9
39	Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay. <i>PLoS ONE</i> , 2019, 14, e0218016.	2.5	13
40	Age at start of using tobacco on the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium (INHANCE). <i>Cancer Epidemiology</i> , 2019, 63, 101615.	1.9	12
41	Population preferences for breast cancer screening policies: Discrete choice experiment in Belarus. <i>PLoS ONE</i> , 2019, 14, e0224667.	2.5	8
42	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. <i>Journal of Infectious Diseases</i> , 2019, 220, 1609-1619.	4.0	17
43	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
44	Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer. <i>International Journal of Cancer</i> , 2019, 145, 2042-2050.	5.1	13
45	Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach. <i>Oral Oncology</i> , 2019, 94, 47-57.	1.5	32
46	Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study. <i>The Lancet Global Health</i> , 2019, 7, e772-e783.	6.3	56
47	Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali, Colombia. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 7, 112-117.	4.5	14
48	Systematic reviews as a "lens of evidence": Determinants of benefits and harms of breast cancer screening. <i>International Journal of Cancer</i> , 2019, 145, 994-1006.	5.1	43
49	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2019, 111, 923-932.	6.3	249
50	Prevalence of Atrophic Gastritis in Kazakhstan and the Accuracy of Pepsinogen Tests to Detect Gastric Mucosal Atrophy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3825-3829.	1.2	7
51	Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. <i>Contemporary Clinical Trials</i> , 2018, 68, 35-44.	1.8	12
52	The epidemiology of <i>Helicobacter pylori</i> infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review. <i>Helicobacter</i> , 2018, 23, e12483.	3.5	81
53	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 205-212.	6.3	71
54	Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies. <i>Vaccine</i> , 2018, 36, 4774-4782.	3.8	103

#	ARTICLE	IF	CITATIONS
55	Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). <i>Virology</i> , 2018, 516, 86-101.	2.4	35
56	Toward the World Code Against Cancer. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	6
57	Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. <i>PLoS Pathogens</i> , 2018, 14, e1007352.	4.7	77
58	Impact of operational factors on HPV positivity rates in an HPV-based screening study in Colombia. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 44-51.	2.3	1
59	Accuracy of two plasma antibody tests and faecal antigen test for non-invasive detection of <i>H. pylori</i> in middle-aged Caucasian general population sample. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 777-783.	1.5	12
60	T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. <i>PLoS ONE</i> , 2018, 13, e0178167.	2.5	14
61	Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort. <i>International Journal of Cancer</i> , 2017, 140, 1926-1934.	5.1	10
62	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw300.	6.3	43
63	The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. <i>Sexually Transmitted Diseases</i> , 2017, 44, 442-449.	1.7	10
64	Effect of <i>Helicobacter pylori</i> Eradication on Gastric Cancer Prevention in Korea: A Randomized Controlled Clinical Trial. , 2017, , 315-330.		0
65	Multicentric randomised study of <i>Helicobacter pylori</i> eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. <i>BMJ Open</i> , 2017, 7, e016999.	1.9	53
66	Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. <i>Lancet, The</i> , 2017, 389, 861-870.	13.7	171
67	Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland. <i>PLoS ONE</i> , 2017, 12, e0170189.	2.5	36
68	Population-Based Strategies for <i>Helicobacter pylori</i> -Associated Disease Management: Latin American Perspective. , 2016, , 503-517.		1
69	Cervical cancer in Central and South America: Burden of disease and status of disease control. <i>Cancer Epidemiology</i> , 2016, 44, S121-S130.	1.9	59
70	Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia. <i>Cancer Prevention Research</i> , 2016, 9, 766-771.	1.5	25
71	Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. <i>Nature Genetics</i> , 2016, 48, 1544-1550.	21.4	164
72	Socio-demographic and reproductive determinants of cervical neoplasia in seven sub-Saharan African countries. <i>Cancer Causes and Control</i> , 2016, 27, 1437-1446.	1.8	14

#	ARTICLE	IF	CITATIONS
73	Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. <i>The Lancet Global Health</i> , 2016, 4, e453-e463.	6.3	580
74	Quantitative Detection and Genotyping of <i>Helicobacter pylori</i> from Stool using Droplet Digital PCR Reveals Variation in Bacterial Loads that Correlates with <i>cagA</i> Virulence Gene Carriage. <i>Helicobacter</i> , 2016, 21, 325-333.	3.5	37
75	Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 30-38.	3.3	31
76	World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 132, 252-258.	2.3	134
77	Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 212.e1-212.e15.	1.3	108
78	Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. <i>Journal of Infectious Diseases</i> , 2016, 213, 939-947.	4.0	18
79	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv302.	6.3	92
80	Low frequency of cigarette smoking and the risk of head and neck cancer in the INHANCE consortium pooled analysis. <i>International Journal of Epidemiology</i> , 2016, 45, 835-845.	1.9	40
81	Implementation of HPV testing for cervical cancer screening in programmatic contexts: The Jujuy demonstration project in Argentina. <i>International Journal of Cancer</i> , 2015, 137, 1709-1718.	5.1	36
82	Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. <i>International Journal of Cancer</i> , 2015, 136, 1125-1139.	5.1	112
83	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology</i> , The, 2015, 16, 775-786.	10.7	247
84	Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. <i>BMJ</i> , The, 2015, 351, h4358.	6.0	32
85	Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. <i>The Lancet Global Health</i> , 2015, 3, e85-e94.	6.3	177
86	Hepatitis C virus seroprevalence in the general female population from 8 countries. <i>Journal of Clinical Virology</i> , 2015, 68, 89-93.	3.1	7
87	Present status of human papillomavirus vaccine development and implementation. <i>Lancet Oncology</i> , The, 2015, 16, e206-e216.	10.7	165
88	Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. <i>Lancet Oncology</i> , The, 2015, 16, e226-e233.	10.7	66
89	Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. <i>International Journal of Epidemiology</i> , 2015, 44, 169-185.	1.9	128
90	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. <i>Vaccine</i> , 2015, 33, 2141-2151.	3.8	17

#	ARTICLE	IF	CITATIONS
91	European Code against Cancer 4th Edition: Infections and Cancer. <i>Cancer Epidemiology</i> , 2015, 39, S120-S138.	1.9	34
92	Genetic Variants in Nicotine Addiction and Alcohol Metabolism Genes, Oral Cancer Risk and the Propensity to Smoke and Drink Alcohol: A Replication Study in India. <i>PLoS ONE</i> , 2014, 9, e88240.	2.5	27
93	Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2965-2974.	3.3	7
94	Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1890-1899.	4.0	17
95	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju400-dju400.	6.3	24
96	Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays. <i>Frontiers in Oncology</i> , 2014, 3, 328.	2.8	24
97	Immunosuppression in cervical cancer with special reference to arginase activity. <i>Gynecologic Oncology</i> , 2014, 135, 74-80.	1.4	23
98	The fight against gastric cancer – the IARC Working Group report. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1107-1114.	2.4	135
99	Prevention of Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1197.	7.4	82
100	Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. <i>European Journal of Epidemiology</i> , 2014, 29, 35-48.	5.7	66
101	An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters. <i>American Journal of Epidemiology</i> , 2014, 180, 545-555.	3.4	87
102	Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates. <i>American Journal of Epidemiology</i> , 2014, 180, 599-607.	3.4	14
103	Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. <i>Vaccine</i> , 2014, 32, 5087-5097.	3.8	92
104	Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. <i>Vaccine</i> , 2014, 32, 725-732.	3.8	79
105	Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. <i>BMC Infectious Diseases</i> , 2014, 14, 120.	2.9	22
106	Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. <i>International Journal of Cancer</i> , 2014, 135, 2453-2461.	5.1	51
107	Management of <i>Helicobacter pylori</i> infection in Latin America: A Delphi technique-based consensus. <i>World Journal of Gastroenterology</i> , 2014, 20, 10969.	3.3	23
108	Prevention Strategies for Gastric Cancer: A Global Perspective. <i>Clinical Endoscopy</i> , 2014, 47, 478.	1.5	107

#	ARTICLE	IF	CITATIONS
109	Location and Density of Immune Cells in Precursor Lesions and Cervical Cancer. <i>Cancer Microenvironment</i> , 2013, 6, 69-77.	3.1	28
110	<i>Helicobacter pylori</i> Eradication in the Prevention of Gastric Cancer: Are More Trials Needed?. <i>Current Oncology Reports</i> , 2013, 15, 517-525.	4.0	17
111	Prevalence of and Risk Factors for Oral Human Papillomavirus Among Young Women in Costa Rica. <i>Journal of Infectious Diseases</i> , 2013, 208, 1643-1652.	4.0	47
112	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. <i>American Journal of Epidemiology</i> , 2013, 178, 752-760.	3.4	26
113	Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America. <i>Cancer Causes and Control</i> , 2013, 24, 249-256.	1.8	94
114	Epidemiology of <i>Helicobacter pylori</i> infection in six Latin American countries (SWOG Trial S0701). <i>Cancer Causes and Control</i> , 2013, 24, 209-215.	1.8	102
115	Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2013, 132, 1412-1422.	5.1	123
116	Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1399-1406.	3.3	35
117	Risk of Recurrent <i>Helicobacter pylori</i> Infection 1 Year After Initial Eradication Therapy in 7 Latin American Communities. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 578.	7.4	72
118	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. <i>Cancer Prevention Research</i> , 2013, 6, 1242-1250.	1.5	185
119	Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>American Journal of Epidemiology</i> , 2013, 178, 679-690.	3.4	220
120	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. <i>PLoS ONE</i> , 2013, 8, e53067.	2.5	39
121	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. <i>PLoS ONE</i> , 2013, 8, e68329.	2.5	387
122	Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. <i>PLoS ONE</i> , 2013, 8, e72565.	2.5	47
123	Longitudinal Analysis of Carcinogenic Human Papillomavirus Infection and Associated Cytologic Abnormalities in the Guanacaste Natural History Study: Looking Ahead to Cotesting. <i>Journal of Infectious Diseases</i> , 2012, 205, 498-505.	4.0	5
124	Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican Population. <i>Journal of the National Cancer Institute</i> , 2012, 104, 556-565.	6.3	99
125	Prevalence of and Risk Factors for Anal Human Papillomavirus Infection Among Young Healthy Women in Costa Rica. <i>Journal of Infectious Diseases</i> , 2012, 206, 1103-1110.	4.0	51
126	Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naïve Women in HPV Vaccine Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1547-1554.	2.5	24

#	ARTICLE	IF	CITATIONS
127	Evaluation of the FTA Carrier Device for Human Papillomavirus Testing in Developing Countries. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3870-3876.	3.9	17
128	Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels. <i>Frontiers in Oncology</i> , 2012, 2, 61.	2.8	8
129	Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. <i>Vaccine</i> , 2012, 31, 165-170.	3.8	48
130	Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. <i>International Journal of Cancer</i> , 2012, 131, 211-218.	5.1	29
131	Vitamin or mineral supplement intake and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. <i>International Journal of Cancer</i> , 2012, 131, 1686-1699.	5.1	27
132	Low risk of type-specific carcinogenic HPV re-appearence with subsequent cervical intraepithelial neoplasia grade 2/3. <i>International Journal of Cancer</i> , 2012, 131, 1874-1881.	5.1	29
133	A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. <i>BMC Infectious Diseases</i> , 2012, 12, 33.	2.9	96
134	Switch from cytology-based to human papillomavirus test-based cervical screening: Implications for colposcopy. <i>International Journal of Cancer</i> , 2012, 130, 1879-1887.	5.1	18
135	Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium. <i>Cancer Causes and Control</i> , 2012, 23, 69-88.	1.8	116
136	Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer. <i>PLoS ONE</i> , 2012, 7, e33619.	2.5	37
137	Using Prior Information from the Medical Literature in GWAS of Oral Cancer Identifies Novel Susceptibility Variant on Chromosome 4 - the AdAPT Method. <i>PLoS ONE</i> , 2012, 7, e36888.	2.5	17
138	The Cervical Microbiome over 7 Years and a Comparison of Methodologies for Its Characterization. <i>PLoS ONE</i> , 2012, 7, e40425.	2.5	101
139	Long-Term Persistence of Prevalently Detected Human Papillomavirus Infections in the Absence of Detectable Cervical Precancer and Cancer. <i>Journal of Infectious Diseases</i> , 2011, 203, 814-822.	4.0	47
140	HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. <i>Vaccine</i> , 2011, 29, 2011-2014.	3.8	130
141	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2011, 12, 862-870.	10.7	168
142	Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. <i>Lancet Oncology</i> , The, 2011, 12, 1023-1031.	10.7	98
143	Intrauterine device and cervical cancer: we need more evidence – Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 1186-1187.	10.7	0
144	14-day triple, 5-day concomitant, and 10-day sequential therapies for <i>Helicobacter pylori</i> infection in seven Latin American sites: a randomised trial. <i>Lancet</i> , The, 2011, 378, 507-514.	13.7	239

#	ARTICLE	IF	CITATIONS
145	Prevention of cervical cancer in women's hands: Mexico leads the way. <i>Lancet, The</i> , 2011, 378, 1829-1831.	13.7	4
146	A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium. <i>PLoS Genetics</i> , 2011, 7, e1001333.	3.5	158
147	Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. <i>Sexually Transmitted Diseases</i> , 2011, 38, 976-982.	1.7	18
148	An examination of male and female odds ratios by BMI, cigarette smoking, and alcohol consumption for cancers of the oral cavity, pharynx, and larynx in pooled data from 15 case-control studies. <i>Cancer Causes and Control</i> , 2011, 22, 1217-1231.	1.8	48
149	Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. <i>International Journal of Cancer</i> , 2011, 128, 597-607.	5.1	7
150	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1444-1451.	6.3	274
151	Clustering of Multiple Human Papillomavirus Infections in Women From a Population-Based Study in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2011, 204, 385-390.	4.0	50
152	A Sex-Specific Association between a 15q25 Variant and Upper Aerodigestive Tract Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 658-664.	2.5	14
153	A Competitive Serological Assay Shows Naturally Acquired Immunity to Human Papillomavirus Infections in the Guanacaste Natural History Study. <i>Journal of Infectious Diseases</i> , 2011, 204, 94-102.	4.0	55
154	Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease. <i>Journal of Infectious Diseases</i> , 2011, 203, 910-920.	4.0	245
155	Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. <i>PLoS ONE</i> , 2011, 6, e20183.	2.5	137
156	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. <i>Cancer Discovery</i> , 2011, 1, 408-419.	9.4	143
157	Smoking and Passive Smoking in Cervical Cancer Risk: Pooled Analysis of Couples from the IARC Multicentric Case-control Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1379-1390.	2.5	64
158	The Oral Cavity Contains Abundant Known and Novel Human Papillomaviruses From the Betapapillomavirus and Gammapapillomavirus Genera. <i>Journal of Infectious Diseases</i> , 2011, 204, 787-792.	4.0	162
159	Persistence of Concurrent Infections with Multiple Human Papillomavirus Types: A Population-based Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 823-827.	4.0	33
160	Sequence Imputation of HPV16 Genomes for Genetic Association Studies. <i>PLoS ONE</i> , 2011, 6, e21375.	2.5	70
161	Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2010, 37, 706-714.	1.7	27
162	Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature. <i>Sexually Transmitted Diseases</i> , 2010, 37, 386-391.	1.7	249

#	ARTICLE	IF	CITATIONS
163	Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 340, c712-c712.	2.3	78
164	Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. <i>Archives of Virology</i> , 2010, 155, 367-370.	2.1	11
165	Determinants of seropositivity among HPV-16/18 DNA positive young women. <i>BMC Infectious Diseases</i> , 2010, 10, 238.	2.9	34
166	Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer. <i>PLoS ONE</i> , 2010, 5, e8667.	2.5	104
167	Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. <i>International Journal of Epidemiology</i> , 2010, 39, 166-181.	1.9	322
168	Chlamydia trachomatis and Risk of Prevalent and Incident Cervical Premalignancy in a Population-Based Cohort. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1794-1804.	6.3	63
169	Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. <i>International Journal of Epidemiology</i> , 2010, 39, 182-196.	1.9	210
170	A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. <i>Cancer Research</i> , 2010, 70, 3159-3169.	0.9	221
171	Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1653-1662.	6.3	155
172	Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. <i>International Journal of Epidemiology</i> , 2010, 39, 1091-1102.	1.9	89
173	Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC HPV Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 503-510.	2.5	101
174	Establishment and Operation of a Biorepository for Molecular Epidemiologic Studies in Costa Rica. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 916-922.	2.5	11
175	Body Mass Index, Cigarette Smoking, and Alcohol Consumption and Cancers of the Oral Cavity, Pharynx, and Larynx: Modeling Odds Ratios in Pooled Case-Control Data. <i>American Journal of Epidemiology</i> , 2010, 171, 1250-1261.	3.4	63
176	Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2379-2388.	2.5	46
177	Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3044-3054.	2.5	80
178	Elevated Systemic Levels of Inflammatory Cytokines in Older Women with Persistent Cervical Human Papillomavirus Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1954-1959.	2.5	64
179	Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. <i>Journal of the National Cancer Institute</i> , 2010, 102, 315-324.	6.3	320
180	Genetic Admixture and Population Substructure in Guanacaste Costa Rica. <i>PLoS ONE</i> , 2010, 5, e13336.	2.5	16

#	ARTICLE	IF	CITATIONS
181	Common Genetic Variation in <i>TP53</i> and Risk of Human Papillomavirus Persistence and Progression to CIN3/Cancer Revisited. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1631-1637.	2.5	23
182	Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 863-865.	2.5	51
183	Herpes Simplex Virus Type-2 Seropositivity Among Ever Married Women in South and North Vietnam: A Population-Based Study. <i>Sexually Transmitted Diseases</i> , 2009, 36, 616-620.	1.7	4
184	Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b2569-b2569.	2.3	167
185	Evolutionary Dynamics of Variant Genomes of Human Papillomavirus Types 18, 45, and 97. <i>Journal of Virology</i> , 2009, 83, 1443-1455.	3.4	82
186	Total Exposure and Exposure Rate Effects for Alcohol and Smoking and Risk of Head and Neck Cancer: A Pooled Analysis of Case-Control Studies. <i>American Journal of Epidemiology</i> , 2009, 170, 937-947.	3.4	143
187	Determinants and Correlation of Systemic and Cervical Concentrations of Total IgA and IgG. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2672-2676.	2.5	10
188	Geographic Variation in the Prevalence of Kaposi Sarcoma—Associated Herpesvirus and Risk Factors for Transmission. <i>Journal of Infectious Diseases</i> , 2009, 199, 1449-1456.	4.0	79
189	Type of Alcoholic Beverage and Risk of Head and Neck Cancer—A Pooled Analysis Within the INHANCE Consortium. <i>American Journal of Epidemiology</i> , 2009, 169, 132-142.	3.4	85
190	Factors Associated with Fluctuations in IgA and IgG Levels at the Cervix during the Menstrual Cycle. <i>Journal of Infectious Diseases</i> , 2009, 199, 455-463.	4.0	25
191	Human Papillomavirus (HPV) Vaccines: Limited Cross-Protection against Additional HPV Types. <i>Journal of Infectious Diseases</i> , 2009, 199, 919-922.	4.0	97
192	Family history of cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>International Journal of Cancer</i> , 2009, 124, 394-401.	5.1	122
193	Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. <i>International Journal of Cancer</i> , 2009, 125, 1649-1656.	5.1	15
194	EUROGIN 2008 roadmap on cervical cancer prevention. <i>International Journal of Cancer</i> , 2009, 125, 2246-2255.	5.1	33
195	Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 541-550.	2.5	908
196	Common Variants in Immune and DNA Repair Genes and Risk for Human Papillomavirus Persistence and Progression to Cervical Cancer. <i>Journal of Infectious Diseases</i> , 2009, 199, 20-30.	4.0	107
197	Treatability by Cryotherapy in a Screen-and-Treat Strategy. <i>Journal of Lower Genital Tract Disease</i> , 2009, 13, 174-181.	1.9	15
198	An Evaluation by Midwives and Gynecologists of Treatability of Cervical Lesions by Cryotherapy Among Human Papillomavirus-Positive Women. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 728-733.	2.5	6

#	ARTICLE	IF	CITATIONS
199	Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada. <i>Oral Oncology</i> , 2008, 44, 242-250.	1.5	113
200	Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. <i>Vaccine</i> , 2008, 26, 3608-3616.	3.8	77
201	New Approaches to Cervical Cancer Screening in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L49-L58.	3.8	35
202	Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L88-L95.	3.8	40
203	Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L96-L107.	3.8	44
204	Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. <i>Vaccine</i> , 2008, 26, 4795-4808.	3.8	145
205	Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. <i>Journal of the National Cancer Institute</i> , 2008, 100, 513-517.	6.3	436
206	Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. <i>International Journal of Epidemiology</i> , 2008, 37, 536-546.	1.9	141
207	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3437-3445.	3.9	75
208	Epidemiology of Genital Chlamydia trachomatis Infection Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2008, 35, 461-468.	1.7	18
209	Comparison of the SPF 10^5 -LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1447-1454.	3.9	74
210	Alcohol Drinking in Never Users of Tobacco, Cigarette Smoking in Never Drinkers, and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>Journal of the National Cancer Institute</i> , 2007, 99, 777-789.	6.3	837
211	Evaluation of a Novel PCR-Based Assay for Detection and Identification of <i>Chlamydia trachomatis</i> Serovars in Cervical Specimens. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3986-3991.	3.9	25
212	Human Papillomavirus Vaccine Should Be Given before Sexual Debut for Maximum Benefit. <i>Journal of Infectious Diseases</i> , 2007, 196, 1431-1432.	4.0	31
213	Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 743.	7.4	581
214	Identification and characterization of two novel human papillomaviruses (HPVs) by overlapping PCR: HPV102 and HPV106. <i>Journal of General Virology</i> , 2007, 88, 2952-2955.	2.9	21
215	CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 441-446.	1.4	200
216	A Comparison of Cervical and Vaginal Human Papillomavirus. <i>Sexually Transmitted Diseases</i> , 2007, 34, 849-855.	1.7	73

#	ARTICLE	IF	CITATIONS
217	The Natural History of Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Among Young Women in the Guanacaste Cohort Shortly After Initiation of Sexual Life. <i>Sexually Transmitted Diseases</i> , 2007, 34, 494-502.	1.7	51
218	Cervical Infection With <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in Women From Ten Areas in Four Continents. <i>Sexually Transmitted Diseases</i> , 2007, 34, 563-569.	1.7	42
219	Identification of a novel human papillomavirus (HPV97) related to HPV18 and HPV45. <i>International Journal of Cancer</i> , 2007, 121, 193-198.	5.1	16
220	High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. <i>International Journal of Cancer</i> , 2007, 121, 2787-2793.	5.1	134
221	Human papillomavirus (HPV) types 101 and 103 isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-papillomaviruses. <i>Virology</i> , 2007, 360, 447-453.	2.4	58
222	Type-Specific Seroprevalence of Herpes Simplex Virus Type 2 and Associated Risk Factors in Middle-Aged Women From 6 Countries: The IARC Multicentric Study. <i>Sexually Transmitted Diseases</i> , 2007, 34, 1019-1024.	1.7	23
223	Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. <i>Sexually Transmitted Diseases</i> , 2007, 34, 1019-24.	1.7	17
224	Preparing Digitized Cervigrams for Colposcopy Research and Education: Determination of Optimal Resolution and Compression Parameters. <i>Journal of Lower Genital Tract Disease</i> , 2006, 10, 39-44.	1.9	11
225	Diet and body mass, and oral and oropharyngeal squamous cell carcinomas: Analysis from the IARC multinational case-control study. <i>International Journal of Cancer</i> , 2006, 118, 2293-2297.	5.1	73
226	Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. <i>International Journal of Cancer</i> , 2006, 119, 2677-2684.	5.1	332
227	Reproductive Factors, Oral Contraceptive Use, and Human Papillomavirus Infection: Pooled Analysis of the IARC HPV Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2148-2153.	2.5	118
228	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. <i>Cancer Research</i> , 2006, 66, 11070-11076.	0.9	98
229	Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution. <i>Cancer Research</i> , 2006, 66, 1218-1224.	0.9	95
230	Sexual Behavior, Condom Use, and Human Papillomavirus: Pooled Analysis of the IARC Human Papillomavirus Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 326-333.	2.5	163
231	Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic Abnormality. <i>Cancer Research</i> , 2006, 66, 10112-10119.	0.9	105
232	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. <i>Journal of the National Cancer Institute</i> , 2006, 98, 303-315.	6.3	568
233	The carcinogenicity of human papillomavirus types reflects viral evolution. <i>Virology</i> , 2005, 337, 76-84.	2.4	487
234	Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors. <i>International Journal of Cancer</i> , 2005, 113, 483-489.	5.1	59

#	ARTICLE	IF	CITATIONS
235	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2005, 115, 329-332.	5.1	59
236	Re: Muñoz et al., "Against which human papillomavirus types shall we vaccinate and screen? The international perspective." <i>Int J Cancer</i> 2004;111:278-85. <i>International Journal of Cancer</i> , 2005, 115, 670-670.	5.1	0
237	Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: Results from two studies conducted in Costa Rica and the United States. <i>International Journal of Cancer</i> , 2005, 116, 599-605.	5.1	24
238	Chlamydia trachomatis Infection in Female Partners of Circumcised and Uncircumcised Adult Men. <i>American Journal of Epidemiology</i> , 2005, 162, 907-916.	3.4	79
239	Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. <i>Journal of Experimental Medicine</i> , 2005, 201, 1069-1075.	8.5	209
240	Epidemiologic Profile of Type-Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1796-1807.	4.0	322
241	A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests. <i>Journal of the National Cancer Institute</i> , 2005, 97, 147-150.	6.3	128
242	Diversifying Selection in Human Papillomavirus Type 16 Lineages Based on Complete Genome Analyses. <i>Journal of Virology</i> , 2005, 79, 7014-7023.	3.4	148
243	A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1808-1816.	4.0	354
244	Codetection of a Mixed Population of HPV62 Containing Wild-Type and Disrupted E1 Open Reading Frame in a 45-Year-Old Woman with Normal Cytology. <i>Journal of Infectious Diseases</i> , 2004, 190, 1303-1309.	4.0	5
245	Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 324-327.	2.5	177
246	A Population-Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. <i>Journal of Infectious Diseases</i> , 2004, 190, 458-467.	4.0	72
247	Human Papillomavirus Type 16 and TP53 Mutation in Oral Cancer. <i>Cancer Research</i> , 2004, 64, 468-471.	0.9	98
248	The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. <i>International Journal of Cancer</i> , 2004, 108, 741-749.	5.1	219
249	<i>Chlamydia trachomatis</i> and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. <i>International Journal of Cancer</i> , 2004, 111, 431-439.	5.1	218
250	Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions. <i>Vaccine Journal</i> , 2004, 11, 399-405.	3.1	33
251	Performance of Direct Visual Inspection of the Cervix with Acetic Acid and Magnification in a Previously Screened Population. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 132-138.	1.9	7
252	Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10 000 women in Guanacaste, Costa Rica. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2004, 15, 75-89.	1.1	74

#	ARTICLE	IF	CITATIONS
253	Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 2271-6.	2.5	43
254	Correlates of IL-10 and IL-12 concentrations in cervical secretions. <i>Journal of Clinical Immunology</i> , 2003, 23, 175-183.	3.8	39
255	Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. <i>Cancer Causes and Control</i> , 2003, 14, 805-814.	1.8	299
256	Stability of archived liquid-based cervical cytologic specimens. <i>Cancer</i> , 2003, 99, 89-96.	4.1	49
257	Innovations in understanding the biology of cervical cancer. <i>Cancer</i> , 2003, 98, 2064-2069.	4.1	35
258	Stability of archived liquid-based cytologic specimens. <i>Cancer</i> , 2003, 99, 320-322.	4.1	8
259	Prevalence of human papillomavirus infection in women in Busan, South Korea. <i>International Journal of Cancer</i> , 2003, 103, 413-421.	5.1	116
260	Human papillomavirus infection among women in South and North Vietnam. <i>International Journal of Cancer</i> , 2003, 104, 213-220.	5.1	124
261	Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case-control study. <i>International Journal of Cancer</i> , 2003, 107, 127-133.	5.1	126
262	Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 518-527.	27.0	5,264
263	Population-Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand. <i>Journal of Infectious Diseases</i> , 2003, 187, 1246-1256.	4.0	130
264	Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1772-1783.	6.3	1,013
265	Prevalence of Human Papillomavirus Infection Among Women in Concordia, Argentina. <i>Sexually Transmitted Diseases</i> , 2003, 30, 593-599.	1.7	93
266	Cervical Human Papillomavirus Infection in the Female Population in Barcelona, Spain. <i>Sexually Transmitted Diseases</i> , 2003, 30, 788-793.	1.7	126
267	Right-Sided Ectocervical Lesions May Be Associated with False-Negative Cytology Among Women with Histologic Cervical Intraepithelial Neoplasia 2 or 3. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 175-183.	1.9	2
268	A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 477-84.	2.5	39
269	A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 815-23.	2.5	16
270	Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1449-56.	2.5	10

#	ARTICLE	IF	CITATIONS
271	Enhanced Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Virus-Like Particles of Human Papillomavirus. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1755-1760.	3.9	63
272	Evidence for <i>Chlamydia trachomatis</i> as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer in Brazil and the Philippines. <i>Journal of Infectious Diseases</i> , 2002, 185, 324-331.	4.0	210
273	Comprehensive Analysis of Human Leukocyte Antigen Class I Alleles and Cervical Neoplasia in 3 Epidemiologic Studies. <i>Journal of Infectious Diseases</i> , 2002, 186, 598-605.	4.0	59
274	Herpes Simplex Virus-2 as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1604-1613.	6.3	299
275	Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. <i>Lancet, The</i> , 2002, 359, 1085-1092.	13.7	561
276	Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. <i>Lancet, The</i> , 2002, 359, 1093-1101.	13.7	482
277	Can cervicography be improved? An evaluation with arbitrated cervicography interpretations. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 15-23.	1.3	22
278	Comparisons of HPV DNA detection by MY09/11 PCR methods. <i>Journal of Medical Virology</i> , 2002, 68, 417-423.	5.0	158
279	Oral cancer in southern India: The influence of smoking, drinking, paan-chewing and oral hygiene. <i>International Journal of Cancer</i> , 2002, 98, 440-445.	5.1	258
280	Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. <i>New England Journal of Medicine</i> , 2002, 346, 1105-1112.	27.0	707
281	Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 1394-9.	2.5	57
282	High Prevalence of Human Papillomavirus Infection in Mexican Males. <i>Sexually Transmitted Diseases</i> , 2001, 28, 277-280.	1.7	75
283	Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infection Among Middle-Age Women in Brazil and the Philippines. <i>Sexually Transmitted Diseases</i> , 2001, 28, 187-194.	1.7	42
284	Epidemiology of HPV infection among Mexican women with normal cervical cytology. <i>International Journal of Cancer</i> , 2001, 91, 412-420.	5.1	277
285	Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. <i>International Journal of Cancer</i> , 2001, 94, 520-526.	5.1	30
286	Human Leukocyte Antigen Class I and II Alleles and Risk of Cervical Neoplasia: Results from a Population-Based Study in Costa Rica. <i>Journal of Infectious Diseases</i> , 2001, 184, 1310-1314.	4.0	94
287	Human papillomavirus infection and invasive cervical cancer in Paraguay. <i>International Journal of Cancer</i> , 2000, 85, 486-491.	5.1	99
288	HPV DNA Testing in Cervical Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 87.	7.4	466

#	ARTICLE	IF	CITATIONS
289	Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica. <i>Journal of the National Cancer Institute</i> , 2000, 92, 464-474.	6.3	515
290	Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. <i>Journal of Immunological Methods</i> , 1999, 225, 131-143.	1.4	47
291	Cervicography screening for cervical cancer among 8460 women in a high-risk population. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 290-298.	1.3	56
292	Epidemiologic determinants of vaginal pH. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 1060-1066.	1.3	52
293	Utility of liquid-based cytology for cervical carcinoma screening. <i>Cancer</i> , 1999, 87, 48-55.	4.1	199
294	Performance of a semiautomated papanicolaou smear screening system. <i>Cancer</i> , 1998, 84, 273-280.	4.1	35
295	Risk Factors for Cervical Cancer in Thailand: a Case-Control Study. <i>Journal of the National Cancer Institute</i> , 1998, 90, 50-57.	6.3	179
296	Collection of Cervical Secretions Does Not Adversely Affect Pap Smears Taken Immediately Afterward. <i>Vaccine Journal</i> , 1998, 5, 491-493.	2.6	13
297	Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. <i>Cancer</i> , 1997, 81, 89-97.	4.1	99
298	Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 1997, 1, 362-375.	1.1	183
299	The relations between cervical cancer and serological markers of nutritional status. <i>Nutrition and Cancer</i> , 1994, 21, 193-201.	2.0	30
300	Risk Factors for Cervical Cancer by Histology. <i>Gynecologic Oncology</i> , 1993, 51, 301-306.	1.4	65
301	Screening for Cervical Cancer in Latin America: A Case-Control Study. <i>International Journal of Epidemiology</i> , 1992, 21, 1050-1056.	1.9	79
302	A Case-Control Study of Nutrient Status and Invasive Cervical Cancer. <i>American Journal of Epidemiology</i> , 1991, 134, 1335-1346.	3.4	100
303	A Case-Control Study of Nutrient Status and Invasive Cervical Cancer. <i>American Journal of Epidemiology</i> , 1991, 134, 1347-1355.	3.4	82
304	Injectable contraceptives and risk of invasive cervical cancer: Evidence of an association. <i>International Journal of Cancer</i> , 1990, 46, 5-7.	5.1	35
305	Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. <i>Cancer</i> , 1990, 65, 380-386.	4.1	131
306	Oral Contraceptive Use and Risk of Invasive Cervical Cancer. <i>International Journal of Epidemiology</i> , 1990, 19, 4-11.	1.9	107

#	ARTICLE	IF	CITATIONS
307	Invasive Cervical Cancer and Smoking in Latin America. Journal of the National Cancer Institute, 1989, 81, 205-211.	6.3	61
308	The male factor in the etiology of cervical cancer among sexually monogamous women. International Journal of Cancer, 1989, 44, 199-203.	5.1	111
309	Human Papillomavirus Infection and Cervical Cancer in Latin America. New England Journal of Medicine, 1989, 320, 1437-1441.	27.0	229
310	PARITY AS A RISK FACTOR FOR CERVICAL CANCER. American Journal of Epidemiology, 1989, 130, 486-496.	3.4	152
311	Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial. Sexually Transmitted Infections, 0, , sextrans-2022-055434.	1.9	0